Investigating the effect of adding whey protein in the prevention of severe physiologic jaundice in full term infant
Not Applicable
Recruiting
- Conditions
- eonatal physiological icterus.Neonatal jaundice, unspecifiedP59.9
- Registration Number
- IRCT20230618058522N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Healthy term newborns (gestational age more than 37 weeks)
Written consent from parents
Exclusion Criteria
Hospitalization of the infant on the first day of birth due to icterus
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bilirubin. Timepoint: Measurement of skin bilirubin on the first day of birth and 5 days after the intervention. Method of measurement: Standard skin bilirubin measurement device.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie whey protein's effect on bilirubin metabolism in IRCT20230618058522N1?
How does maternal whey protein supplementation in IRCT20230618058522N1 compare to phototherapy for severe neonatal jaundice prevention?
Which biomarkers predict response to maternal whey protein in IRCT20230618058522N1 for neonatal physiological icterus prevention?
What are the potential adverse effects of maternal whey protein supplementation in IRCT20230618058522N1 on breastfeeding infants?
Are there synergistic effects of combining whey protein with other neonatal jaundice prevention strategies in IRCT20230618058522N1?